Study of SNIPR001 for resistant gut bacteria before stem cell transplant
Part of Infections clinical trials.
This study tests an experimental oral medicine called SNIPR001. It is designed to reduce resistant E. coli bacteria in the gut before your stem cell transplant, possibly lowering the risk of infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a blood cancer (such as leukemia, lymphoma, or myeloma).
- You are scheduled to receive a stem cell transplant from a donor.
- You carry a specific type of E. coli bacteria in your gut that is resistant to the antibiotic levofloxacin (your doctor can test for this).
- You are willing to take the antibiotic levofloxacin as part of your transplant care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an oral “fecal microbiotherapy” treatment given before and around an allogeneic (donor) stem-cell transplant to help prevent transplant-related complications. It may help by improving gut and immune function during the high-risk transplant period.
This Phase 2 study tests whether an investigational treatment can help clear or reduce antibiotic-resistant bacteria living in the gut. It may help prevent these germs from causing future infections by targeting specific resistant bacteria found on stool or rectal swabs.
This trial tests an investigational drug called SPN01 to see if it is safe and how the body processes it. It includes both healthy volunteers and people with colorectal cancer who are scheduled for surgery.
This study will track how certain hard-to-treat bacteria spread and cause infections in people who are in the intensive care unit (ICU) or have had a stem cell transplant. The goal is to better understand and prevent these infections in vulnerable patients.
This trial tests whether giving a transplant of healthy gut bacteria (fecal microbiota transplant) before a stem cell transplant can improve outcomes for people with certain blood cancers or bone marrow disorders.
This Phase 1 study tests whether transferring stool microbiome (a fecal microbiota transplant) can help clear antibiotic-resistant bacteria living in the gut. It’s meant for children and teens who have had infections from these resistant bacteria and who can safely take the study’s planned treatment.
Hear when a new E Coli Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.